Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation
Language English Country Slovakia Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Transplantation, Autologous MeSH
- Chromosome Aberrations * MeSH
- Cytogenetic Analysis MeSH
- Adult MeSH
- In Situ Hybridization, Fluorescence MeSH
- Immunoglobulin Light Chains genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Chromosomes, Human, Pair 11 genetics MeSH
- Chromosomes, Human, Pair 14 genetics MeSH
- Chromosomes, Human, Pair 4 genetics MeSH
- Survival Rate MeSH
- Multiple Myeloma genetics pathology therapy MeSH
- Prognosis MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Translocation, Genetic genetics MeSH
- Stem Cell Transplantation * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Immunoglobulin Light Chains MeSH
Malignant plasma cells in multiple myeloma (MM) are frequently characterized by complex karyotypes and chromosome instability. These cytogenetic changes are considered important prognostic indicators in MM patients. We have studied samples from 68 patients with newly diagnosed MM who were treated with high-dose chemotherapy and autologous stem cell transplantation. G-banding revealed abnormal karyotypes in 14 of 55 patients (25%) who had informative conventional cytogenetics. The combination of cytoplasmic immunoglobulin light chain labeling and interphase fluorescent in situ hybridization (cIg-FISH) revealed the presence of genetic aberrations in 53 of 68 patients (78%). Chromosome 13 abnormalities were found in 33 patients (50%) and IgH rearrangements in 36 patients (56.25%). In IgH positive patients we performed subsequent examinations of IgH affecting translocations t(4;14) and t(11;14) and we found translocation t(11;14) in 8 patients (12.5%) and t(4;14) in 10 patients (15.5%). The occurrences of others chromosomal abnormalities with known prognostic impact in MM were as follows: del(17)(p13) was present in 5 patients (9.8%) and gain 1q21 in 14 patients (36%). Analysis of survival of patients with different cytogenetic abnormalities revealed shorter overall survival (OS) in patients with IgH rearrangements (p=0.020) and trend to shorter OS in patients with gain 1q21 (p=0.064), respectively. Remarkably, patients with two or more aberrations had significantly shorter overall survival (p=0.001), time to progression (p=0.036) and progression free survival (p=0.008). Our results show a high incidence of chromosomal abnormalities in MM patients and confirm the prognostic impact of selected chromosomal aberrations as well as cumulative effect of multiple cytogenetic changes occurring simultaneously.
References provided by Crossref.org
Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse
